A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss (COSMOS-DIGITAL)

Community Outreach Support and Engagement Using Online Strategies - Decentralized Insights Into Therapy Adoption and Value

This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active community of people using anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss to examine the willingness of participants to engage in a digital study, provide consent, and complete various study-related tasks, including a self-collected capillary blood sample for assay testing and health related surveys.

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Device: TAP® Micro Select Device (Touch Activated Phlebotomy)

• Study Type: Observational
• Enrollment (Actual): 200

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Medford, Massachusetts, United States, 02155
      • YourBio Health/CRT

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Adults using the anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss.

Description

Inclusion Criteria:

• Adults 18 - 80 years of age.
• Living in the United States.
• Consented from the Inspire online platform patient community for COSMOS-DIGITAL.
• Self-Reported current use of, and intention to continue for at least 30 days, one of the following medications for the indications of weight management/obesity:
• Semaglutide (wegovy)
• Tirzepatide (zepbound)

Exclusion Criteria:

• Currently receiving treatment in another investigational device or drug study, or participation in a current clinical trial.
• Self-reported sensitivity/allergy to any of the components of the self-draw collection device including stainless steel or elements commonly found in stainless steel.
• Self-reported fear of blood.
• Self-reported circulatory conditions causing difficulty in drawing capillary blood.
• Known history of bleeding diathesis or any coagulation disorder.
• History of skin disorders, abnormal skin integrity or atypical skin health within the areas to be tested in the upper arm.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Adults Using Anti-Obesity Medications; Adults using the anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss to examine the willingness of patients to engage in a digital study, provide consent, and complete various study-related tasks.	Device: TAP® Micro Select Device (Touch Activated Phlebotomy); The TAP Micro Select device will be used in an investigational capacity by participants for self-collection of whole capillary blood.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of Participants with Self-blood Draw Received by Central Laboratory	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Consented Participants with Complete Self-reported Survey for Medical History		Day 1
Percentage of Consented Participants with Complete Self-reported Survey for Nausea and Nausea Management		Day 1 and Day 30
Percentage of Consented Participants with Complete Self-reported Survey for Patient Reported Outcomes in Obesity		Day 1 and Day 30
Percentage of Consented Participants with Complete Self-reported Survey for Partners in Health (PiH) Questionnaire		Day 1 and Day 30
Percentage of Consented Participants with Complete Self-reported Survey for the Daily Diary	The daily diary will record answers about nausea symptoms.	30 days
Percentage of Consented Participants with Complete Self-reported Survey for the Satisfaction Survey	Participants will be asked about their satisfaction with using the device for the self-blood draw.	Day 30
Percentage of Participants with Sufficient Volume of Blood Collected for Sampling		30 days

Collaborators and Investigators

• Sponsor: Amgen
• Investigators: Study Director: MD, Amgen

Publications and helpful links

Helpful Links

• AmgenTrials clinical trials website

Study record dates

Study Major Dates

• Study Start (Actual): November 14, 2024
• Primary Completion (Actual): January 6, 2025
• Study Completion (Actual): January 6, 2025

Study Registration Dates

• First Submitted: January 1, 2025
• First Submitted That Met QC Criteria: January 1, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 13, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Body Weight; Overweight; Obesity
• Other Study ID Numbers: 20240163

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
• IPD Sharing Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
• IPD Sharing Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes